Clinical Trial

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients

Study acronym: AML-VAC-XS15
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2024 (before its estimated May 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.
Trial Details
NCT Number NCT06252584
Lead Sponsor University Hospital Tuebingen
Conditions Acute Myeloid Leukemia, Adult
Enrollment 20 participants
Start Date 2024-05-02
Primary Completion 2026-05-02 (estimated)
Study Completion 2026-11-02 (estimated)
Updated on ClinicalTrials.gov 2024-02-09